Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lymphoma 42Leukemia 34Lymphoma, Large B-Cell, Diffuse 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia, Myeloid, Acute 24Burkitt Lymphoma 19Leukemia, Myelomonocytic, Acute 16Lung Neoplasms 15Leukemia, Monocytic, Acute 15Neuroblastoma 14Leukemia, Megakaryoblastic, Acute 14Leukemia, Erythroblastic, Acute 14Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 13Hodgkin Disease 12Congenital Abnormalities 12Carcinoma, Non-Small-Cell Lung 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Central Nervous System Neoplasms 10Sarcoma 9Myelodysplastic Syndromes 9Anemia, Refractory, with Excess of Blasts 8Small Cell Lung Carcinoma 7Myeloproliferative Disorders 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Neoplasms 6Multiple Myeloma 6Lymphoma, B-Cell, Marginal Zone 6

Interventions

lutetium Lu 177 dotatate 5Specimen Handling 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 3cabozantinib 2X-Rays 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2romidepsin 1peposertib 1pembrolizumab 1pazopanib 1olaparib 1fludarabine 1belinostat 1aldesleukin 1Sunitinib 1Sorafenib 1Salts 1Octreotide 1Nivolumab 1Lactones 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Everolimus 1Etoposide 1Disulfides 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroendocrine Tumors × Etoposide × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡